Pricing Log in Create free account
Saturday 7 November 2026 Export LXRX’s income statement to Excel — free account

Lexicon Pharmaceuticals, Inc.

LXRX Healthcare Biotechnology

Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024.

Revenue
−20.7%
EPS
+21.3%
Free cash flow
+66.1%
Total debt
−8.17%

Quarter to September 2026, against a year earlier

1.79 0.18 +11.18%
Market cap
$716.4M
P/E
0.0×
Fwd P/E
−8.4×
Dividend yield
—
F-score
4/9
Altman Z
−12.11
Beneish M
−1.17
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 2.72
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 5 — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 50.79%

Capital & Financial Ratios $m

Size
Market Cap 716.37
Revenue ttm 38.54
Net income ttm (62.35)
Free cash flow ttm (49.23)
Net debt Q (131.31)
Valuation
P/E 0.00
Forward P/E (8.35) (negative: loss-making)
Price / sales 20.67 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 4.86
Financial health
Current ratio Q 10.63 (at or above 1.5: strong)
Debt / equity Q 0.32 (at or below 0.5: strong)
Interest coverage Q (12.80)
Growth
Revenue growth Q −20.67% (below 0%: shrinking)
Operating income growth Q −18.94% (below 0%: shrinking)
EPS, this year −14.16% (below 0%: weak)
EPS, next year A −32.68% (below 0%: weak)
Revenue, next year A −25.37% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +8.11%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 17.4×, against a ten-year median of 13.0×; over the ten years it ranged from 0.6× in 2020 to 4,508× in 2023.
P/S against its own 10 years 59.53%
10-year low 10-year high
P/B against its own 10 years 59.89%
10-year low 10-year high
EV/Sales against its own 10 years 57.22%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 170 238 96 183
Receivables 1 3 2 2
Inventory 0 0 0 1
Other — — — —
177 246 102 189
2023 2024 2025 Q'26
Payables 14 15 3 4
ST’ Debt — — 5 —
Other — — — —
32 45 21 18

Compound Annual Growth %

10y 5y 3y
Sales (9.15%) 15.72% 610.25%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (9.31%) (7.21%) (2.81%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.06 Actual −0.06

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.07 −0.04 Beat by 0.03
Q4 FY25 −0.07 −0.04 Beat by 0.03
Q1 FY26 −0.04 0.00 Beat by 0.04
Q2 FY26 −0.06 −0.06 Met by 0.00
Q3 FY26 −0.06 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.00 (0.07) (0.03) — —
’25 (0.07) 0.01 (0.04) (0.04) (0.14)
’24 (0.20) (0.17) (0.18) (0.09) (0.63)
’23 (0.17) (0.22) (0.21) (0.20) (0.79)
’22 (0.16) (0.16) (0.13) (0.16) (0.62)
’21 (0.15) (0.13) (0.16) (0.17) (0.60)
’20 (0.63) (0.65) 0.71 (0.04) (0.53)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 21 1 11 — —
’25 1 29 14 5 50
’24 1 2 2 27 31
’23 0 0 0 1 1
’22 0 0 0 0 0
’21 0 0 0 0 0
’20 8 9 7 0 24
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (9) (8) — —
’25 (44) 17 (24) (17) (68)
’24 (55) (49) (54) (21) (179)
’23 (32) (38) (42) (51) (162)
’22 (23) (24) (19) (22) (89)
’21 (25) (22) (17) (23) (87)
’20 (22) (46) (40) (34) (143)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (9) (8) — —
’25 (44) 17 (24) (17) (68)
’24 (55) (49) (54) (22) (180)
’23 (32) (38) (42) (51) (162)
’22 (23) (24) (19) (23) (90)
’21 (25) (23) (17) (23) (88)
’20 (22) (46) (40) (23) (132)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 79 92 63 322 24 0 0 1 31 50 39 (5.0%) 37 17 71 +12.7%
Gross margin, % 100.00 97.93 96.06 99.00 91.96 100.00 100.00 92.94 98.02 99.45 98.89 (0.5) pt
EBT (131) (136) (121) 124 (59) (88) (102) (177) (200) (50) (62) (10.1%)
EBT margin, % (165.85) (147.95) (190.71) 38.54 (244.11) (29,448.99) (73,341.01) (14,710.88) (644.78) (101.08) (161.80) +64.8 pt
Net income (131) (123) (121) 130 (59) (88) (102) (177) (200) (50) (62) (10.1%)
Per share, $
Per share, $ Revenue 0.76 0.87 0.60 3.03 0.22 0.00 0.00 0.01 0.10 0.14 0.09 (17.4%)
Earnings (1.36) (1.23) (1.14) 1.23 (0.53) (0.60) (0.62) (0.79) (0.63) (0.14) (0.14) (22.3%)
Cash flow (1.69) (1.76) (1.40) 1.07 (1.29) (0.60) (0.54) (0.73) (0.56) (0.19) (0.11) (21.7%)
Capex 0.00 0.00 0.00 0.00 0.10 (0.01) (0.01) 0.00 0.00 0.00 0.00 n/m
Free cash flow (1.69) (1.76) (1.41) 1.07 (1.19) (0.61) (0.54) (0.73) (0.56) (0.19) (0.11) (21.7%)
Book value 1.52 0.65 (0.25) 1.10 1.41 0.78 0.71 0.42 0.46 0.30 0.37 (16.6%)
Shares, m 104 105 106 106 111 146 166 221 320 363 411 +14.9%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 3.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.3
P/S 18.61 11.62 11.12 1.37 15.80 1,925.73 2,372.72 292.02 7.62 8.38 20.67 466.5
P/B 9.37 15.60 0.00 3.76 2.42 5.05 2.82 3.78 1.62 3.88 4.86 4.8
EV/Sales 15.52 10.91 12.46 1.29 9.96 1,642.30 1,736.13 234.53 3.23 7.54 17.38 367.4
EV/FCF (6.99) (5.39) (5.30) 3.64 (1.81) (5.55) (2.68) (1.74) (0.56) (5.45) (13.32) (3.2)
Cash, $m
Cash, $m Operating cash flow (176) (185) (149) 114 (143) (87) (89) (162) (179) (68) (49) (10.0%)
Capex 0 0 0 0 11 (1) (1) 0 (1) — (1) +20.6%
Free cash flow (176) (186) (149) 114 (132) (88) (90) (162) (180) (68) (49) (10.0%)
Balance, $m
Balance, $m Working capital 193 217 137 272 111 67 118 145 201 81 171 (9.2%)
Net debt (245) (65) 85 (26) (140) (84) (88) (71) (138) (42) (131) (17.7%)
Shareholders’ equity 157 68 (26) 117 156 114 117 93 146 108 164 (4.1%)
Returns, %
Returns, % ROA (23.31) (26.97) (33.45) 37.08 (18.85) (51.52) (61.56) (83.60) (75.93) (20.83) (27.84) +2.5 pt
ROIC 0.00 (2,594.22) (110.26) 97.55 (182.69) (186.85) (219.91) (475.14) (1,485.93) (46.81) (109.13) (46.8) pt
ROE (59.31) (109.00) (575.96) 286.97 (42.84) (65.01) (88.37) (168.50) (167.66) (39.72) (43.91) +19.6 pt
People
People Employees 168 174 202 184 78 87 135 285 103 81 — (7.8%)
Revenue/emp, $m 0.47 0.53 0.31 1.75 0.31 0.00 0.00 0.00 0.30 0.61 — +3.0%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Lexicon Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ANNX Annexon, Inc. $759.3M — (loss-making) — — n/m −26.41% (below 0%: shrinking) 0.00% 0.00% Compare
ARDX Ardelyx, Inc. $751.6M — (loss-making) — (loss-making) +15.70% (above 0%: growing) n/m +938.76% (above 0%: growing) 96.44% 3.15% Compare
LXRX Lexicon Pharmaceuticals, Inc. $716.4M — (loss-making) — (loss-making) −20.67% (below 0%: shrinking) n/m +66.10% (above 0%: growing) 99.30% (128.84%)
OABI OmniAb, Inc. $704.5M — (loss-making) — (loss-making) +78.34% (above 0%: growing) n/m +206.33% (above 0%: growing) 92.26% (409.92%) Compare
SANA Sana Biotechnology, Inc. $700.5M — (loss-making) — — n/m −5.46% (below 0%: shrinking) 0.00% 0.00% Compare
CGEM Cullinan Therapeutics, Inc. $695.0M — (loss-making) 4.8× — n/m +33.66% (above 0%: growing) 100.00% 0.00% Compare
ATTO Attovia Therapeutics, Inc. $684.8M — — — n/m — 100.00% (4,845.11%) Compare
DNA Ginkgo Bioworks Holdings, Inc. $670.7M — (loss-making) — (loss-making) −59.37% (below 0%: shrinking) n/m −16.38% (below 0%: shrinking) 91.47% (290.47%) Compare
SLDB Solid Biosciences Inc. $662.7M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −39.56% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $697.8M — — −21.83% — −5.46% 91.87% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 16 March 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 3.55m 5.80m 60.00
2023 4.11m 3.06m 80.00

Ownership

Directors and executive officers, together 14.00%
Invus, L.P. and related parties 48.30%
Raymond Debbane 12.20%
FMR LLC 9.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Lexicon Pharmaceuticals, Inc. (LXRX) Latest News

6 Nov

Impact 3 · · MarketBeat transcript

5 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · GuruFocus.com
Impact 3 · · The Motley Fool transcript

23 Oct

Impact 4 · · GlobeNewswire

21 Oct

Impact 3 · · GlobeNewswire

2 Oct

Impact 4 · · Simply Wall St.

28 Sep

Impact 4 · · Investing.com
Impact 3 · · The Motley Fool

25 Sep

Impact 3 · · GlobeNewswire

20 Sep

Impact 4 · · MarketBeat

31 Aug

Impact 3 ·

24 Aug

Impact 4 ·

13 Aug

Impact 4 · · The Motley Fool transcript

7 Aug

Impact 3 ·

6 Aug

Impact 4 · transcript
Impact 3 · · MarketBeat transcript
Impact 3 ·

30 Jul

Impact 4 ·

27 Jul

Impact 4 ·

1 Jun

Impact 3 · · The Motley Fool transcript

13 May

Impact 4 · · Simply Wall St.

10 May

Impact 4 · · Insider Monkey

8 May

Impact 3 · · MarketBeat

7 May

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

4 May

Impact 4 · · GlobeNewswire

3 May

Impact 4 · · Simply Wall St.

1 May

Impact 4 · · Insider Monkey

27 Apr

Impact 4 · · Simply Wall St.
stockrow.com/LXRX · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com